IP Library Granted Patent US 8,815,954
Granted Patent B2
US 8,815,954 · App. 11/617,551 · Granted Aug 26, 2014

Arginine heteromers for topical administration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,815,954
App. No.
11/617,551
Granted
Aug 26, 2014
Kind
B2
Abstract

The invention is directed to a strategy for providing therapeutic or cosmetic benefit to skin by topically applying arginine chemically bound to a second (non-oligoarginine) compound in order to increase transepithelial delivery of arginine through a combination of increased solubility and flux across the skin. The arginine heteromers of the invention can add other complementary or beneficial properties for the skin beyond those that are arginine-related.

Claims (16)

1. A topical composition comprising a heteromer of formula I:

A-R  I

wherein A is arginine and R is retinoic acid, and A and R are covalently bound by an amide linkage via an amino group of the arginine, such that the guanadino group of the arginine remains unreacted,

wherein the heteromer has greater flux across the skin than arginine alone; and

wherein the topical composition further comprises a dermatologically acceptable carrier or vehicle for topical application.

2. The composition of claim 1 further comprising skin-care preparations.

3. The composition of claim 1 further comprising bath-preparations.

4. The composition of claim 1 further comprising cosmetic preparations.

5. The composition of claim 1 further comprising eye-care preparations.

6. The composition of claim 1 further comprising lip-care preparations.

7. The composition of claim 1 further comprising sunscreen preparations.

8. The composition of claim 1 further comprising hair care preparations.

9. The composition of claim 1 further comprising an anti-acne preparation.

10. The composition of claim 1 further comprising anti-oxidant preparations.

11. The composition of claim 1 further comprising anti-psoriasis preparations.

12. The composition of claim 1 further comprising corticosteroid preparations.

Assignments (10)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2019
From: HERCULES CAPITAL, INC. (F/K/A HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 050565/0300 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 24432/321, 24432/284, 24432/317, 22432/187, AND 22756/549 Recorded Oct 4, 2011
From: LEADER VENTURES, LLC
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 027015/0658 →
SECURITY AGREEMENT Recorded Sep 22, 2011
From: REVANCE THERAPEUTICS, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 026953/0726 →
SECURITY AGREEMENT Recorded May 29, 2009
From: REVANCE THERAPEUTICS, INC.
To: LEADER VENTURES, LLC
Reel/Frame 022756/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2007
From: WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 018768/0065 →